238 related articles for article (PubMed ID: 17436565)
1. DNA repair mechanisms are involved in the hypoxia-dependent toxicity of NLCQ-1 (NSC 709257) and its synergistic interaction with alkylating agents.
Papadopoulou MV; Bloomer WD
In Vivo; 2007; 21(2):175-80. PubMed ID: 17436565
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms involved in the potentiation of paclitaxel or 5-fU by the hypoxic cytotoxin NLCQ-1 (NSC 709257) in vitro.
Papadopoulou MV; Ji X; Bloomer WD
Anticancer Res; 2005; 25(3B):2161-70. PubMed ID: 16158959
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms involved in the potentiation of melphalan by the bioreductive compound THNLA-1 in vitro.
Papadopoulou MV; Ji M; Khan SH; Bloomer WD
Oncol Res; 1999; 11(8):345-57. PubMed ID: 10803738
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of alkylating agents by NLCQ-1 or TPZ in vitro and in vivo.
Papadopoulou MV; Ji X; Bloomer WD
J Exp Ther Oncol; 2006; 5(4):261-72. PubMed ID: 17024967
[TBL] [Abstract][Full Text] [Related]
5. NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug.
Papadopoulou MV; Bloomer WD
Clin Cancer Res; 2003 Nov; 9(15):5714-20. PubMed ID: 14654556
[TBL] [Abstract][Full Text] [Related]
6. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
Papadopoulou MV; Ji M; Rao MK; Bloomer WD
Oncol Res; 2001; 12(8):325-33. PubMed ID: 11589303
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization.
Taverna P; Hwang HS; Schupp JE; Radivoyevitch T; Session NN; Reddy G; Zarling DA; Kinsella TJ
Cancer Res; 2003 Feb; 63(4):838-46. PubMed ID: 12591735
[TBL] [Abstract][Full Text] [Related]
8. Recovery from sublethal and potentially lethal damage in an X-ray-sensitive CHO cell.
Schwartz JL; Giovanazzi S; Weichselbaum RR
Radiat Res; 1987 Jul; 111(1):58-67. PubMed ID: 3602355
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.
Papadopoulou MV; Ji M; Ji X; Bloomer WD; Hollingshead MG
Cancer Chemother Pharmacol; 2002 Dec; 50(6):501-8. PubMed ID: 12451478
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-dependent retinal toxicity of NLCQ-1 (NSC 709257) in BALB/c mice. Comparison with tirapazamine.
Papadopoulou MV; Ji M; Bloomer WD
Basic Clin Pharmacol Toxicol; 2011 Jun; 108(6):396-9. PubMed ID: 21205223
[TBL] [Abstract][Full Text] [Related]
11. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice.
Papadopoulou MV; Ji M; Bloomer WD
Cancer Chemother Pharmacol; 2001 Aug; 48(2):160-8. PubMed ID: 11561782
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells.
Fracasso PM; Sartorelli AC
Cancer Res; 1986 Aug; 46(8):3939-44. PubMed ID: 3089583
[TBL] [Abstract][Full Text] [Related]
13. The role of nonhomologous DNA end joining, conservative homologous recombination, and single-strand annealing in the cell cycle-dependent repair of DNA double-strand breaks induced by H(2)O(2) in mammalian cells.
Frankenberg-Schwager M; Becker M; Garg I; Pralle E; Wolf H; Frankenberg D
Radiat Res; 2008 Dec; 170(6):784-93. PubMed ID: 19138034
[TBL] [Abstract][Full Text] [Related]
14. Effect of deficiencies in DNA repair on the toxicity of mitomycin C and porfiromycin to CHO cells under aerobic and hypoxic conditions.
Hughes CS; Irvin CG; Rockwell S
Cancer Commun; 1991 Feb; 3(2):29-35. PubMed ID: 1899798
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo; comparison with tirapazamine.
Papadopoulou MV; Ji M; Ji X; Bloomer WD
Cancer Chemother Pharmacol; 2002 Oct; 50(4):291-8. PubMed ID: 12357303
[TBL] [Abstract][Full Text] [Related]
16. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1): a novel DNA-affinic bioreductive agent as chemosensitizer. I.
Papadopoulou MV; Ji M; Rao MK; Bloomer WD
Oncol Res; 1997; 9(5):249-57. PubMed ID: 9306432
[TBL] [Abstract][Full Text] [Related]
17. NLCQ-1, a novel hypoxic cytotoxin: potentiation of melphalan, cisDDP and cyclophosphamide in vivo.
Papadopoulou MV; Ji M; Bloomer WD
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):775-9. PubMed ID: 9845094
[TBL] [Abstract][Full Text] [Related]
18. Synergistic enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-1, in vivo: comparison with tirapazamine.
Papadopoulou MV; Ji M; Bloomer WD
Oncol Res; 2002; 13(1):47-54. PubMed ID: 12201674
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of DNA repair in cells treated with a combination of alkylating agents.
Frankfurt OS; Seckinger D; Sugarbaker EV
Anticancer Res; 1993; 13(4):947-52. PubMed ID: 8352564
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin.
Kovacs MS; Hocking DJ; Evans JW; Siim BG; Wouters BG; Brown JM
Br J Cancer; 1999 Jun; 80(8):1245-51. PubMed ID: 10376978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
